Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. (Skye) on August 18, 2026. The filing addresses a notice of delisting received from The Nasdaq Stock Market LLC due to non-compliance with minimum stockholders' equity requirements. Additionally, the report provides updates regarding a proposed acquisition of Redx Pharma Limited (Redx).
Key Financial Metrics
- Stockholders' Equity: ($497,307) as of June 30, 2026 (based on the Q2 2026 Form 10-Q).
- Nasdaq Compliance Threshold: $2,500,000 minimum stockholders' equity required under Listing Rule 5550(b)(1).
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or margins for the current period.
- Debt and Liquidity: Specific debt levels and liquidity ratios are not disclosed in this document.
Material Changes and Listing Status
On August 18, 2026, Skye received a written notification from Nasdaq stating that the Company failed to meet the $2,500,000 minimum stockholders' equity standard, reporting a negative equity position of ($497,307). The notice has no immediate effect on trading, and the stock will continue to trade under the symbol "SKYE."
- Compliance Timeline: Skye has 45 calendar days (until October 2, 2026) to submit a plan to regain compliance.
- Extension Possibility: If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days (until February 14, 2027) to achieve compliance.
- Appeal Rights: If the plan is not accepted, the Company retains the right to appeal, during which the stock remains listed.
Outlook, Management Commentary, and Risks
Management is currently evaluating various alternative courses of action to regain compliance with Nasdaq listing requirements. There is no assurance that the Company will be able to regain compliance or maintain listing status.
Proposed Transaction: Skye intends to file a proxy statement regarding the proposed acquisition of Redx Pharma Limited. The securities to be issued in this transaction are anticipated to be issued under Section 3(a)(10) of the Securities Act.
Risks and Contingencies:
- Failure to regain Nasdaq compliance or maintain listing standards.
- Uncertainty regarding the consummation of the Redx transaction, including stockholder approval and regulatory clearance.
- Potential disruption to operations and employee retention due to the transaction.
- Competing acquisition proposals or termination of the Transaction Agreement.
Investor Verification Checklist
- Verify the specific plan Skye intends to submit to Nasdaq by October 2, 2026, to address the negative stockholders' equity.
- Review the upcoming Proxy Statement for details on the proposed acquisition of Redx Pharma Limited, including terms and risks.
- Monitor the Company's ability to raise capital or restructure to meet the $2,500,000 equity requirement.
- Check for any updates on the status of the Nasdaq appeal process if the initial compliance plan is rejected.